Cancer Chemotherapy and Pharmacology

, Volume 61, Issue 5, pp 791–802

Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid

Authors

  • Aiping Tong
    • The State Key Laboratory of Biotherapy, West China Hospital, and College of Life ScienceSichuan University
  • Haiyuan Zhang
    • The School of MedicineYangtze University
  • Zhengyu Li
    • The State Key Laboratory of Biotherapy, West China Hospital, and College of Life ScienceSichuan University
  • Lantu Gou
    • The State Key Laboratory of Biotherapy, West China Hospital, and College of Life ScienceSichuan University
  • Zhi Wang
    • Department of Oral Mucosal Diseases, West China Stomatological HospitalSichuan University
  • Haiyan Wei
    • The State Key Laboratory of Biotherapy, West China Hospital, and College of Life ScienceSichuan University
  • Minghai Tang
    • The State Key Laboratory of Biotherapy, West China Hospital, and College of Life ScienceSichuan University
  • Shufang Liang
    • The State Key Laboratory of Biotherapy, West China Hospital, and College of Life ScienceSichuan University
  • Lijuan Chen
    • The State Key Laboratory of Biotherapy, West China Hospital, and College of Life ScienceSichuan University
    • The State Key Laboratory of Biotherapy, West China Hospital, and College of Life ScienceSichuan University
    • The State Key Laboratory of Biotherapy, West China Hospital, and College of Life ScienceSichuan University
Original Article

DOI: 10.1007/s00280-007-0536-2

Cite this article as:
Tong, A., Zhang, H., Li, Z. et al. Cancer Chemother Pharmacol (2008) 61: 791. doi:10.1007/s00280-007-0536-2

Abstract

Purpose

Suberonylanilide hydroxamic acid (SAHA) is an orally administered histone deacetylase inhibitor (HDACI) that has shown significant antitumor activity in a variety of tumor cells. To evaluate if SAHA has an activity against liver cancer, and with an aim to identify the altered cellular factors upon SAHA treatment, human HepG2 cancer cell line was used as a model, and proteomic approach was utilized to elucidate the molecular mechanisms underlying SAHA’s antitumor activity.

Methods

Cell growth inhibition was measured by MTT method, and apoptosis was detected by means of flow cytometry analysis and TUNEL assay. Protein expression profiles were analyzed by 2-DE coupled with MALDI-Q-TOF MS/MS analysis.

Results

A total of 55 differentially expressed proteins were visualized by 2-DE and Coomassie Brilliant Blue (CBB) staining. Of these, 34 proteins were identified via MS/MS analysis. Among the identified proteins, six proteins also displayed significant expression changes at earlier time points upon SAHA treatment, and such alterations were further confirmed by semi-quantitative RT-PCR. Together, at both the mRNA and protein levels, SAHA suppressed the expression of reticulocalbin 1 precursor (RCN1), annexin A3 (ANXA3) and heat shock 27 kDa protein 1 (HSP27), while increasing the expression of aldose reductase (AR), triosephosphate isomerase 1 (TPI) and manganese superoxide dismutase (SOD2).

Conclusion

SAHA remarkably inhibited proliferation of HepG2 cancer cells, and induced apoptosis in vitro. Using proteomics approaches, a variety of differentially expressed proteins were identified in HepG2 cancer cells before and after treatment with SAHA. This study will enable a better understanding of the molecular mechanisms underlying SAHA-mediated antitumor effects at the protein level.

Keywords

Proteomics 2-DE HDACIs Suberonylanilide hydroxamic acid Hepatocellular carcinoma HepG2

Abbreviations

SAHA

Suberonylanilide hydroxamic acid

HADC

Histone deacetylase

HADCIs

Histone deacetylase inhibitors

2-DE

2-Dimensional polyacrylamide gel electrophoresis

HCC

Hepatocellular carcinoma

RCN1

Reticulocalbin 1

ANXA3

Annexin A3

HSP27

Heat shock 27 kDa protein 1

AR

Aldose reductase

TPI

Triosephosphate isomerase 1

SOD2

Manganese superoxide dismutase

Copyright information

© Springer-Verlag 2007